Drug induced toxicity is the leading cause of withdrawal of approved drugs from the market. Identifying potential tissue- or cell-relevant toxicity in the early stages of discovery will save you time and money, ultimately accelerating your route to clinic.
At Aquila, we understand your reasons for investigating cytotoxicity. Whether you need to screen your compound library to find cytotoxic IO drug candidates to take forward, or screen your “hits” for unwanted cytotoxic effects, our immunology experts work closely with you to determine if your compound impacts the viability of both immune and non-immune cells, including tumour cells.
Using our primary cell know-how and custom in vitro assay approach, we can assess apoptosis and necrosis of mixed or isolated cell populations such as PBMCs, T cells, B cells, NK cells, monocytes and DCs in mono- or co-culture set up, with both standard and custom readouts e.g. IncuCyte Live-Cell Analysis System, flow cytometry, ELISA and qPCR.
We also offer Killing Assays to investigate targeted cell death mechanisms. For more information, please click here.
Please get in touch to learn more about our cytotoxicity assay related services.